Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 21, 2021; 27(47): 8166-8181
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8166
Table 5 First pattern of intrahepatic progression in cases with intrahepatic progression

All procedures (n = 100)
TARE_alone (n = 34)
TARE_sorafenib (n = 49)
TARE_no_sorafenib (n = 17)
Progression in treated area75 (75)23 (67.6)40 (81.6)12 (70.6)
   New HCC 34 (34)12 (35.3)19 (38.8)3 (17.6)
   Recurrence/increased enhancement of previously treated HCC20 (20)5 (14.7)9 (26.5)6 (35.3)
   With new MVI8 (8)2 (5.9)6 (12.2)0
   With progressive MVI3 (3)03 (6.1)0
   With mixed patterns110 (10)4 (11.8)3 (6.1)3 (17.6)
Progression in untreated area25 (25)11 (32.4)9 (18.4)5 (29.4)

  • Citation: Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 2021; 27(47): 8166-8181
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i47/8166.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i47.8166